1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Metanomics Health GmbH - Product Pipeline Analysis, 2016 Update

Summary

Metanomics Health GmbH (Metanomics), a subsidiary of BASF SE, is a metabolite profiling company that focuses on metabolic biomarker identification and validation. The analysis of metabolites provides crucial information for various applications in pharma and biotech, biobanking, academia, the food and feed industry and diagnostics fields. It develops novel biomarkers for diagnostic applications in conditions such as early asymptomatic heart failure and type-2 diabetes. The company’s products include MxP Broad Profiling, MxP Targeted Profiling, MxP Isotope Tracer, MetaMap Tox and MxP Quality Control Plasma. It employs fully validated methods to analyze eicosanoic acid, catecholamines, steroids, energy metabolites and lipids. The company out-licenses new metabolic biomarkers to CLIA lab and diagnostic partners. It has operations in Japan and the US. Metanomics is headquartered in Berlin, Germany.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Metanomics Health GmbH
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Table Of Contents

Metanomics Health GmbH - Product Pipeline Analysis, 2016 Update
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Metanomics Health GmbH Company Snapshot 5
Metanomics Health GmbH Company Overview 5
Key Information 5
Metanomics Health GmbH Pipeline Products and Clinical Trials Overview 6
Metanomics Health GmbH - Pipeline Analysis Overview 8
Key Facts 8
Metanomics Health GmbH - Major Products and Services 9
Metanomics Health GmbH Pipeline Products by Development Stage 10
Metanomics Health GmbH Pipeline Products Overview 12
Diagnostic Assay - Multiple Sclerosis 12
Diagnostic Assay - Multiple Sclerosis Product Overview 12
Diagnostic Assay - Pancreatic Cancer 13
Diagnostic Assay - Pancreatic Cancer Product Overview 13
Diagnostic Assay - NSCLC 14
Diagnostic Assay - NSCLC Product Overview 14
Diagnostic Assay - Congestive Heart Failure 15
Diagnostic Assay - Congestive Heart Failure Product Overview 15
Diagnostic Assay - Non-Alcoholic Steatohepatitis 16
Diagnostic Assay - Non-Alcoholic Steatohepatitis Product Overview 16
Diagnostic Assay - Type 2 Diabetes Risk 17
Diagnostic Assay - Type 2 Diabetes Risk Product Overview 17
Prognostic Assay - Prostate Cancer 18
Prognostic Assay - Prostate Cancer Product Overview 18
Prognostic Assay - Congestive Heart Failure 19
Prognostic Assay - Congestive Heart Failure Product Overview 19
Metanomics Health GmbH - Key Competitors 20
Metanomics Health GmbH - Key Employees 21
Metanomics Health GmbH - Locations And Subsidiaries 22
Head Office 22
Other Locations and Subsidiaries 22
Recent Developments 23
Metanomics Health GmbH, Recent Developments 23
Aug 26, 2014: Cenix BioScience and Metanomics Health sign research agreement 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Metanomics Health GmbH, Key Facts 5
Metanomics Health GmbH Pipeline Products and Clinical Trials Overview 6
Metanomics Health GmbH Pipeline Products by Equipment Type 6
Metanomics Health GmbH Pipeline Products by Indication 7
Metanomics Health GmbH, Key Facts 8
Metanomics Health GmbH, Major Products and Services 9
Metanomics Health GmbH Number of Pipeline Products by Development Stage 10
Metanomics Health GmbH Pipeline Products Summary by Development Stage 11
Diagnostic Assay - Multiple Sclerosis - Product Status 12
Diagnostic Assay - Multiple Sclerosis - Product Description 12
Diagnostic Assay - Pancreatic Cancer - Product Status 13
Diagnostic Assay - Pancreatic Cancer - Product Description 13
Diagnostic Assay - NSCLC - Product Status 14
Diagnostic Assay - NSCLC - Product Description 14
Diagnostic Assay - Congestive Heart Failure - Product Status 15
Diagnostic Assay - Congestive Heart Failure - Product Description 15
Diagnostic Assay - Non-Alcoholic Steatohepatitis - Product Status 16
Diagnostic Assay - Non-Alcoholic Steatohepatitis - Product Description 16
Diagnostic Assay - Type 2 Diabetes Risk - Product Status 17
Diagnostic Assay - Type 2 Diabetes Risk - Product Description 17
Prognostic Assay - Prostate Cancer - Product Status 18
Prognostic Assay - Prostate Cancer - Product Description 18
Prognostic Assay - Congestive Heart Failure - Product Status 19
Prognostic Assay - Congestive Heart Failure - Product Description 19
Metanomics Health GmbH, Key Employees 21
Metanomics Health GmbH, Other Locations 22

List of Figures
Metanomics Health GmbH Pipeline Products by Equipment Type 7
Metanomics Health GmbH Pipeline Products by Development Stage 10

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) ...

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H2 2016

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H2 2016 ...

Apolipoprotein E (APOE) - Pipeline Review, H2 2016

Apolipoprotein E (APOE) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Apolipoprotein E (APOE) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Apolipoprotein E (ApoE) - Pipeline Review, H2 2016’, provides in depth analysis on Apolipoprotein E (ApoE) targeted ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.